| FY 2003 |
FY 2004 |
FY 2005 |
Increase or |
|
|---|---|---|---|---|
| Program Level | $17,043,000 |
$6,959,000 |
$0 |
- $6,959,000 |
| Budget Authority |
$17,043,000 |
$6,959,000 |
$0 |
- $6,959,000 |
| Fiscal Year |
Program Level |
Budget Authority |
User Fees |
|---|---|---|---|
| 2001 Actual |
$33,207,000 |
$33,207,000 |
$0 |
| 2002 Actual |
$43,867,000 |
$43,867,000 |
$0 |
| 2003 Actual |
$17,043,000 |
$17,043,000 |
$0 |
| 2004 Enacted |
$6,959,000 |
$6,959,000 |
$0 |
| 2005 Estimate |
$0 |
$0 |
$0 |
The Building and Facilities appropriation provides funding for new construction and for special-purpose laboratories and other facilities and for needed repairs and improvements to existing facilities across the U.S.
The FY 2005 budget requests no new funding for construction or for building improvements or repairs. In an effort to fund other higher priority initiatives, including defending the nation's food supply, meeting cost of living pay increases for our staff, the medical device review program and other emerging needs such as BSE, new funding is not being requested for buildings and facilities. Essential maintenance and repairs for our facilities across nation will be conducted with existing carryover funding.
A strong FDA will ensure a world-class professional work force, effective and efficient operations and adequate resources to accomplish the mission of FDA. The Agency will continue to use base resources to cover the costs of repairs and improvements to FDA facilities, owned and leased. Included are Maryland site components which are now located in approximately 40 buildings in 17 separate locations; plus five regional offices, 19 field District complexes including 19 administrative and 13 specialized laboratory facilities nationwide; more than 150 field resident posts, 16 field criminal investigation offices, two distinct program laboratory complexes outside the Washington D.C. Metro area; and the NCTR complex in Jefferson, Arkansas. With all of these facilities combined, FDA maintains offices and staff in 49 of the 50 States, and in the District of Columbia, Puerto Rico, and the Virgin Islands.
For comparison purposes, industry components regulated by FDA spend between nine percent and 12 percent of the value of their physical plants on maintenance, alteration, and repair, while FDA's spends about two percent on laboratories and laboratory support facilities for the same purpose. This makes it more difficult for FDA scientists to keep pace with the technological advances that fuel incoming premarket applications. Planned repairs and improvement projects, and their estimated costs, that will be delayed or conducted with carryover balances include:
As a part of FDA's plan to restructure its eighteen field laboratories, ARL is one of five multi-disciplined laboratories and will provide laboratory support for a seventeen statewide area and for the U.S-Mexican border stretching from Otay Mesa, California to Brownsville, Texas. The ARL provides analytical support in chemistry and microbiology. The ARL scientists are testing products regulated by the FDA to ensure compliance with the Federal Food, Drug and Cosmetic Act, which will include products produced in the U.S. and imported. The completion of this important facility will remain on hold.
A building dedication ceremony for Phases I & II, the laboratory portion, was held on February 17, 2000. ORA began occupying the laboratory facility in June 2000. The laboratory building is now fully operational. Construction on the fit-out of building 50 floors, five through seven (Phase III) began late summer 2003.
Irvine is also part of FDA's plan to restructure its field laboratories. The contract for construction of Phase I was awarded February 27, 2001 and Phase II was awarded on November 29, 2001. FDA accepted the facility on June 2, 2003. A dedication and ribbon cutting ceremony was held on June 24, 2003. The relocation of the program to the new facility began in July 2003 and was completed in August 2003.